Меню
Набор скоро начнётся NCT06722118

Corticosteroids Before Extubation in Pediatric Intensive Care Unit

Фаза III С лечением Intensive Care Pediatric

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Dexamethasone IV, Placebo.
Кому может быть актуально
Состояния в реестре: Intensive Care Pediatric. Базовые параметры: 2 Days — 6 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Список центров уточняется — проверьте первичный протокол.
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Corticoïdes Avant Extubation en réanimation pédiatrique : étude Multicentrique, Prospective, randomisée, Contre Placebo

Обзор

Fifty to 60% of children admitted to a pediatric intensive care unit (PICU) are placed under invasive mechanical ventilation (MV) at least once during their stay. After extubation, about 30% of these patients will experience respiratory distress due to upper airway obstruction (RDUAO), and about one-third of these cases will require re-intubation. Treating this RDUAO extends the length of stay in the PICU. Pre-extubation corticosteroid therapy has been validated in adults as a preventive treatment for the occurrence of RDUAO. However, the lack of robust data in pediatrics has not allowed for a consensus on the benefit of its use in children on MV in the PICU. The investigators propose to conduct a randomized, multicenter, double-blind, placebo-controlled study evaluating the effect of intravenous dexamethasone (IV-DXM) before extubation on the incidence of RDUAO in children.

Вмешательства

  • Препарат Dexamethasone IV
    IV-DXM 4mg/ml, injectable solution. Dosage of 0.25 mg/kg (maximum 5 mg per dose), prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).
  • Другое Placebo
    Placebo: 0.9% NaCl solution, prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).

Первичные конечные точки

  • Cumulative incidence of respiratory distress due to upper airway obstruction (RDUAO) [Срок оценки: Within 48 hours post-extubation]
Вторичные конечные точки (6)
  • Cumulative incidence of reintubation due to RDUAO [Срок оценки: Within 48 hours following a planned extubation]
  • Odds ratios associated with the occurrence of RDUAO [Срок оценки: Within 48 hours post-extubation]
  • Number of days of hospitalization in pediatric intensive care unit (PICU) [Срок оценки: Up to 28 days]
  • Number of ventilator-free days in PICU [Срок оценки: Up to 28 days]
  • Number of days with non-invasive ventilation (NIV) post-extubation [Срок оценки: Up to 28 days]
  • Incidence of IV-DXM side effects [Срок оценки: Up to 48 hours post-extubation]

Критерии участия

Критерии включения

  • Patients intubated with an endotracheal tube with or without a cuff,
  • Aged from 2 days post-term to 6 years,
  • On mechanical ventilation for at least 36 hours,

And meeting the following extubation criteria:

  • Extubation planned by the medical team
  • Fraction of inspired oxygen (FiO2) ≤ 45%,
  • Oxygen saturation measured by pulse oximeter ≥ 95% or appropriate according to the pathology,
  • Positive end-expiratory pressure (PEEP) ≤ 8 cmH2O,
  • Peak inspiratory pressure ≤ 22 cmH2O or presence of cough.
  • Affiliated with a social security system,
  • Collection of informed consent from the parental authority, by both parents or the legal guardian(s).

Критерии исключения

  • Refusal of consent by at least one parent or by the legal guardian(s),
  • Patient with a contraindication to IV-DXM:
  • Uncontrolled local or general infection,
  • Active viral infections (hepatitis, herpes, chickenpox, shingles),
  • Live vaccines,
  • Severe coagulation disorders,
  • Ongoing gastrointestinal bleeding,
  • Known hypersensitivity to IV-DXM or one of its excipients.
  • Patient participating in another interventional study involving human subjects or being in the exclusion period following a previous study involving human subjects, if applicable,
  • Patient receiving State Medical Aid,
  • Patient on long-term NIV,
  • Known upper airway pathology (UAP) before intubation or at the time of extubation,
  • History of UAP surgery within the month preceding inclusion,
  • Any situation deemed incompatible with the child's participation in the trial at the discretion of the investigating physician,
  • Decision to limit or stop therapeutic interventions.
  • Premature patients aged less than 40 weeks of gestation
  • Newborns aged less than 2 days after post-term birth

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Четверное слепое
Основная цель
Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT06722118 · APHP220674

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗